CEP20

Across TCGA pan-cancer cohorts, CEP20 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CEP20 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CEP20 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CEP20 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where CEP20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	III,IV	0.930	0.480	.015	19	view →
UCEC	OS	Median	All	0.829	0.981	.008	16	view →
LUAD	DFS	Quartile	II,III,IV	0.421	0.888	.040	5	view →
GBM	DFS	Median	All	0.646	0.785	.020	4	view →
CCRCC	OS	Tertile	III,IV	0.977	0.428	.025	4	view →
PDAC	DFS	Median	III,IV	0.361	0.892	.047	3	view →
LSCC	DFS	Quartile	All	0.922	0.745	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CEP20–HNSC (OS)

Open the HNSC breakdown →